%0 Journal Article
%T Effects of Heart Rate Reduction With Either Pyridostigmine or Ivabradine in Patients With Heart Failure: A Randomized, Double
%A Aline Sterque Villacorta
%A Analucia Rampazzo Xavier
%A Ant£¿nio Cl¨¢udio Lucas da N¨®brega
%A Bernardo Campan¨¢rio Precht
%A Cl¨¢udio Tinoco Mesquita
%A Humberto Villacorta
%A Jos¨¦ Ant£¿nio Caldas
%A Let¨ªcia Ubaldo Rodrigues
%A M¨¢rcio Neves
%A Pilar Barreto Porto
%A Salim Kanaan
%J Journal of Cardiovascular Pharmacology and Therapeutics
%@ 1940-4034
%D 2019
%R 10.1177/1074248418799364
%X Heart rate (HR) reduction with ivabradine has been proved to reduce hospitalization and death from heart failure (HF). We sought to investigate whether pyridostigmine would effectively reduce HR in patients with chronic HF as compared with ivabradine. Twenty-one patients with HF who were in sinus rhythm with a resting HR over 70 bpm, despite optimal medical treatment, were included in a randomized, double-blind study comparing pyridostigmine versus ivabradine. The initial dose of ivabradine was 5 mg twice daily to reach a target HR between 50 and 60 bpm and could be titrated to a maximum of 7.5 mg twice daily. Pyridostigmine was used in a fixed dose of 30 mg 3 times daily. The baseline HR for ivabradine and pyridostigmine groups was 89.1 (13.5) and 80.1 (7.2) bpm, respectively (P = .083). After 6 months of treatment, HR was significantly reduced to 64.8 (8.3) bpm in the ivabradine group (P = .0014) and 63.6 (5.9) bpm in the pyridostigmine group (P = .0001). The N-terminal pro-B-type natriuretic peptide was reduced in the ivabradine group (median: 1308.4 [interquartile range: 731-1896] vs 755.8 [134.5-1014] pg/mL; P = .027) and in the pyridostigmine group (132.8 [89.9-829] vs 100.7 [38-360] pg/mL; P = .002). Inflammatory markers interleukin-1, interleukin-6, and tumor necrosis factor were reduced in both groups. Exercise capacity was improved in both groups, with increments in volume of oxygen utilization ( V ¨B O2; ivabradine: 13.1 vs 15.6, P = .048; pyridostigmine: 13.3 vs 16.7, P = .032). Heart rate recovery in the first minute postexercise was improved with pyridostigmine (11.8 [3.9] vs 18 [6.5]; P = .046), but not with ivabradine (13.3 [6.9] vs 14.1 [8.2]; P = .70). No differences in either group were observed in the myocardial scintigraphy with 123-iodine-metaiodobenzylguanidine. Both drugs significantly reduced HR, with improvements in exercise capacity and in neurohormonal and inflammatory profiles
%K heart failure
%K heart rate
%K parasympathetic stimulation
%U https://journals.sagepub.com/doi/full/10.1177/1074248418799364